Doxorubicin vs CMF in the adjuvant treatment of high risk breast cancer

被引：0
|
作者：
Semiglazov, VF [1 ]
Bozhok, AA [1 ]
Ivanova, OA [1 ]
Iranov, VG [1 ]
Golubeva, OM [1 ]
机构：
[1] NN Petrov Oncol Res Inst, St Petersburg, Russia
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80154-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
167
引用
下载
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [1] Doxorubicin vs CMF in the adjuvant treatment of high risk breast cancer
    Semiglazov, VF
    Bozhok, AA
    Moiseyenko, VM
    Ivanova, OA
    Ivanov, VG
    Golubeva, OM
    ANNALS OF ONCOLOGY, 1998, 9 : 5 - 5
  • [2] A Mathematical Model of Breast Cancer Treatment with CMF and Doxorubicin
    Rachel Roe-Dale
    David Isaacson
    Michael Kupferschmid
    Bulletin of Mathematical Biology, 2011, 73 : 585 - 608
  • [3] MELPHALAN VS CMF ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER
    CANELLOS, GP
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1977, 238 (17): : 1851 - 1851
  • [4] A Mathematical Model of Breast Cancer Treatment with CMF and Doxorubicin
    Roe-Dale, Rachel
    Isaacson, David
    Kupferschmid, Michael
    BULLETIN OF MATHEMATICAL BIOLOGY, 2011, 73 (03) : 585 - 608
  • [5] A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
    De Placido, S
    De Laurentiis, M
    De Lena, M
    Lorusso, V
    Paradiso, A
    D'Aprile, M
    Pistillucci, G
    Farris, A
    Sarobba, MG
    Palazzo, S
    Manzione, L
    Adamo, V
    Palmeri, S
    Ferraù, F
    Lauria, R
    Pagliarulo, C
    Petrella, G
    Limite, G
    Costanzo, R
    Bianco, AR
    BRITISH JOURNAL OF CANCER, 2005, 92 (03) : 467 - 474
  • [6] A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
    S De Placido
    M De Laurentiis
    M De Lena
    V Lorusso
    A Paradiso
    M D'Aprile
    G Pistillucci
    A Farris
    M G Sarobba
    S Palazzo
    L Manzione
    V Adamo
    S Palmeri
    F Ferraù
    R Lauria
    C Pagliarulo
    G Petrella
    G Limite
    R Costanzo
    A R Bianco
    British Journal of Cancer, 2005, 92 : 467 - 474
  • [7] Adjuvant treatment in high risk breast cancer
    Jones, A
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 1996, 55 (04): : 156 - 158
  • [8] ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER USING CMFVP VS CMF VS CMF-MER - A CALGB STUDY
    WEISS, RB
    KORZUN, AH
    TORMEY, DC
    HOLLAND, JF
    WEINBERG, VE
    WOOD, WC
    BREAST CANCER RESEARCH AND TREATMENT, 1984, 4 (04) : 339 - 339
  • [9] Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer.
    Batey, MA
    Wright, JG
    Simmonds, D
    Proctor, M
    Chapman, F
    Fishwick, K
    Azzabi, A
    Newell, DR
    Lind, MJ
    Calvert, AH
    Boddy, AV
    BRITISH JOURNAL OF CANCER, 1999, 80 : 93 - 93
  • [10] Adjuvant treatment in high-risk breast cancer
    Mansi, JL
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 1996, 56 (2-3): : 112 - 112
12345